Lurbinectedin’s Mechanism in Ovarian Cancer
Lurbinectedin (trade name Zepzelca) binds covalently to DNA minor grooves, trapping topoisomerase I and blocking double-strand break repair. This triggers DNA damage response pathways, leading to cell cycle arrest and apoptosis, particularly in transcriptionally active tumor cells.[1]
In ovarian cancer cells, which often overexpress DNA repair deficiencies (e.g., BRCA mutations or homologous recombination defects), lurbinectedin exploits these vulnerabilities. It stalls RNA polymerase II at transcription sites, causing accumulation of R-loops—RNA-DNA hybrids that induce replication stress and catastrophic DNA breaks. Ovarian tumors with high tumor mutational burden or platinum resistance show heightened sensitivity due to impaired repair mechanisms.[2][3]
How It Differs from Chemotherapy
Unlike platinum drugs (e.g., carboplatin), which crosslink DNA directly, lurbinectedin targets transcription-dependent processes. This reduces resistance in platinum-refractory ovarian cancers, where cells upregulate repair pathways. Preclinical studies in ovarian cell lines (e.g., A2780, SKOV3) demonstrate lurbinectedin induces more persistent γH2AX foci—markers of unrepaired DNA damage—than platinums alone.[4]
Clinical Response in Ovarian Cancer Trials
In phase II trials like PM14-501 (NCT02454972), lurbinectedin monotherapy yielded 24% overall response rates in platinum-resistant ovarian cancer, with median progression-free survival of 4.1 months. Responses lasted longer in patients with low HRD scores, linking efficacy to baseline DNA repair status.[5] Combination with pegylated liposomal doxorubicin boosted rates to 32%.[6]
Why Ovarian Cells Are Vulnerable
Ovarian cancers frequently harbor TP53 mutations (96% prevalence) and HRD (50%+ cases), amplifying lurbinectedin's cytotoxicity. It downregulates SLFN11, a sensor of replication stress absent in many resistant lines, restoring sensitivity.[7] No specific patents cover its ovarian targeting; general composition-of-matter protection expires around 2028 in the US.[8]
Common Resistance Mechanisms
Resistance emerges via SLFN11 loss or TOP1 overexpression, seen in 20-30% of relapsed ovarian cases. Combination strategies (e.g., with PARP inhibitors like olaparib) overcome this by dual DNA damage blockade.[9]
[1] Nat Rev Clin Oncol, 2019
[2] Mol Cancer Ther, 2018
[3] Clin Cancer Res, 2020
[4] Mol Cancer Ther, 2018
[5] J Clin Oncol, 2020
[6] Gynecol Oncol, 2021
[7] Nat Rev Clin Oncol, 2019
[8] DrugPatentWatch.com
[9] Cancer Discov, 2022